Jump to main navigation Skip to Content

DFG Logo: back to Homepage Deutsche Forschungsgemeinschaft

DFG Contacts

Stand: October 8, 2019

Dr. Stefan Thiel

Programme Director
Life Sciences 3: Medicine

E-Mail: stefan.thiel@dfg.de
Telephone: +49 (228) 885-2977
Telefax: +49 (228) 885-713320
Kennedyallee 40
53175 Bonn

Tasks and Responsibilities

General Responsibilities

Clinical Trials
Coordination - Cancer Research

Support of DFG Statutory Bodies

Hinterzarten Circle on Cancer Research

Scientific Areas of Responsibility

205-14 Hematology, Oncology, Transfusion Medicine
205-31 Radiation Oncology and Radiobiology

Scientific Areas of Responsibility (Deputy Contact)

205-06 Pathology
205-25 General and Visceral Surgery

Coordinated Programmes (procedural matters)

Clinical Research Units

286 Exploiting defects in the DNA damage response for the treatment of chronic lymphocytic leukemia
344 Untangling and Targeting Mechanisms of Myelofibrosis in Myeloproliferative Neoplasms (MPN)

Priority Programmes

2084 µBONE: Colonization and interaction of tumor cells within the bone microenvironment

Research Units

2033 The Hematopoietic Niches
2314 Targeting therapeutic windows in essential cellular processes for tumor therapy
2674 Aging-related epigenetic remodeling in acute myeloid leukemia

Coordinated Programmes (scientific matters)


221 Modulation of graft-versus-host and graft-versus leukemia immune responses after allogeneic stem cell transplantation
240 Platelets – Molecular, cellular and systemic functions in health and disease

Clusters of Excellence (ExStra)

2180 Image-Guided and Functionally Instructed Tumor Therapies (iFIT)

Collaborative Research Centres

850 Control of Cell Motility in Morphogenesis, Cancer Invasion and Metastasis
873 Maintenance and Differentiation of Stem Cells in Development and Disease
1074 Experimental Models and Clinical Translation in Leukemia
1243 Genetic and Epigenetic Evolution of Hematopoietic Neoplasms
1399 Mechanisms of drug sensitivity and resistance in small cell lung cancer

Research Training Groups

2375 Tumor-Targeted Drug Delivery